Avanzanite Bioscience Launches Novel Business Model to Commercialize Innovative Medicines for Rare Diseases in Europe
Today, Avanzanite Bioscience B.V. (“Avanzanite” or the “Company”) officially launches its commercial-stage enterprise, seeking to expand patient access to medicines for rare diseases in Europe while unlocking revenue and growth potential for emerging research-based biopharmaceutical originators. Avanzanite, a fully authorized distributor of medicinal products, partners with these biopharmaceutical collaborators through flexible, bespoke licensing and distribution partnerships across Europe. The Company’s novel business model enables the global commercialization of promising medicines and addresses the unsustainable inequities in access to innovative orphan drugs across Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115005069/en/
Avanzanite CEO and Founder, Adam Andrzej Plich (Photo: Business Wire)
Avanzanite was established to address a critical market need in the European orphan drug landscape due to the complexity and cost of streamlining business operations across 30+ countries given a limited number of patients and an increasingly challenging market access environment. In fact, most European launches of orphan drugs – some experts claim as high as 80% – fail to meet their commercial and revenue goals and do not reach patients in need. The result of these unique market dynamics leaves emerging biopharmaceutical companies unmotivated or ill-equipped to establish European operations or enter certain countries. As a result, there are an increasing number of biopharmaceutical companies either opting not to launch their new orphan medicines in Europe or exiting the market altogether. These dynamics are particularly damaging to emerging biopharmaceutical originators that are the driving force of global pharmaceutical innovation, especially for rare diseases. Ultimately, the patients are the ones paying the price by missing out on promising therapies.
Avanzanite’s Founder and CEO, Adam Plich, stated, “We are providing a market-driven solution for the issue of access to orphan medicines in Europe.”
“Our inspiration and the initial validation of our unique business model stems from our collaboration and an exclusive license agreement with SIFI S.p.A. (“SIFI”), a leading international ophthalmic company headquartered in Italy.” Mr. Plich continued, “SIFI partnered with Avanzanite to commercialize and distribute its investigational ultra-orphan medicine for the treatment of Acanthamoeba Keratitis (AK) – a devastating, highly resistant eye infection that accounts for 50% of blindness among contact lens users – across 26 countries within the European Economic Area and Switzerland.” After more than 15 years of research & development efforts, the European Medicines Agency (“EMA”) is currently reviewing the product for marketing approval.
“When evaluating commercialization options for our orphan medicine in multiple European territories,” stated Fabrizio Chines, SIFI Chairman and CEO. “Avanzanite made a compelling case as to why it would be best positioned to commercialize and, in fact, provide the broadest market access through its unique business model.” Mr. Chines continued, "Mr. Plich and his team demonstrated an impressive track record of managing the complexities of product launches across the fragmented European marketplace, particularly regarding pricing & reimbursement, physician engagement and technical operations.”
Mr. Plich has a proven track record of successful product launches in Europe. Most recently, he founded and led a boutique advisory firm supporting U.S. and European biopharmaceutical companies on corporate strategy and product launch. Previously, he served as a Vice President at Teva Pharmaceuticals where he led all pricing and market access activities in the European marketplace. Anant Murthy, Co-Founder and Board Advisor, also brings a demonstrated track record of successful orphan medicine launches and is currently the EMEA General Manager at Argenx. Previously, Murthy was a Vice President at Alnylam where he led pricing & market access for EMEA & Canada and was the General Manager of mid-size EU markets and Canada. Additionally, Avanzanite benefits from the deep expertise of its Advisory Board: Dawn Sherman, CEO of LabConnect; Daniel A. de Boer, CEO at ProQR; and Leopoldo Zambeletti, an independent healthcare corporate finance advisor. The Company has also established critical infrastructure and hired key leaders across commercialization and technical operations areas.
Avanzanite is advancing discussions with several biopharmaceutical companies seeking to enter the European market in order to expand its portfolio breadth. Given the high number of investigational drugs in development for orphan diseases, Avanzanite envisions significant opportunity to expand patient access and optimize value creation for originators. Avanzanite sees its near-term growth opportunity in late-stage or approved ultra- or other overlooked orphan medicines. Mr. Plich concluded, “We’ve cracked the code in deciphering this tricky landscape, and now, with our initial strategic partnership with SIFI, we are ready to take our transformational model to the next level by bringing new medicines to patients with rare diseases.”
ABOUT AVANZANITE BIOSCIENCE: Founded in 2021, by biopharmaceutical executives, Adam Plich and Anant Murthy, Avanzanite is on a mission to redefine the commercialization of orphan medicines to improve patient access across Europe and beyond. Derived from the word ‘Tanzanite’ – one of the rarest and most underappreciated gemstones on earth – Avanzanite was formed to capitalize on two primary objectives, one economic, and one humanitarian. The economic goal is to offer end-to-end commercialization and distribution partnership with research-based biopharmaceutical originators to unlock the full value of their orphan medicines in European markets; this is the unique expertise and core competency of the Avanzanite team through its decades of operating experience navigating this area. Equally important, the Company's humanitarian goal stems from our commitment to enabling access to novel medicines for patients who suffer from orphan diseases regardless of where in Europe they live. Avanzanite is fully authorized to distribute medicinal products throughout the European Economic Area.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Crash Bandicoot Returns in All-new Team Based, Four vs. Four, Competitive Showdown, Crash Team Rumble ™9.12.2022 04:30:00 CET | Press release
Get ready to team up and throw down, because Crash and his friends (and foes) are back, and this time there will be some unexpected, fur-ocious competition! In development by the talented team at Toys for Bob who brought fans the acclaimed Crash Bandicoot™ 4: It’s About Time™, Crash Team Rumble™is an all-new 4v4, team-based online multiplayer video game set in Crash Bandicoot’s vibrant and zany universe. Published by Activision Publishing, Inc., Crash Team Rumblewill release on PlayStation®5, PlayStation®4, Xbox® Series X/S and Xbox One® in 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221208005292/en/ Crash Team Rumble Gameplay Screenshot (Photo: Business Wire) In Crash Team Rumble, fans can play as Crash, Dingodile, and a host of other friends and frenemies, each of which has their own distinct power, personality, and playstyle, as they compete across wild and varied arenas in 4v4 team-based online multiplayer actio
Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast Cancer9.12.2022 00:00:00 CET | Press release
Initial results from the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan (Dato-DXd) showed encouraging and durable efficacy in patients with heavily pretreated hormone receptor (HR) positive, HER2 low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridization [ISH]-) or HER2 negative (IHC 0) unresectable or metastatic breast cancer. Safety data were consistent with previous trials of datopotamab deruxtecan. Results were presented today as a Spotlight Poster Discussion (Abstract #PD13-08) at the 2022 San Antonio Breast Cancer Symposium (#SABCS22). Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN). Approximately 70% of breast cancer tumors are considered HR positive and HER2 low or negative.1 For patients with HR positive, HER2 low or negative metastatic breast cancer that progress on or are not suitable candidates for endocrine the
TreviPay Acquires Apruve8.12.2022 23:45:00 CET | Press release
TreviPay, a leader in global B2B payments and invoicing solutions, today announced the signing of a definitive agreement to acquire payment platform Apruve. Apruve offers a robust suite of payment solutions for global enterprises that will complement and expand on TreviPay’s existing order-to-cash technology offerings, merchant invoicing solutions, and the geographical reach of TreviPay’s existing B2B networks. TreviPay has experienced unprecedented demand from global enterprise buyers and sellers resulting in 30% organic growth in 2022, and this acquisition furthers TreviPay's plans to expand its order-to-cash technology offerings and B2B payment network. This acquisition builds on TreviPay’s recent purchase of Baton Financial Services. “TreviPay provides payment and invoicing solutions for a number of leading manufacturers and OEMs; the acquisition of Apruve will accelerate our advancement in the technology manufacturing vertical and expand our geographic reach into key Asian markets
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy8.12.2022 22:05:00 CET | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the CONTACT-01 study did not meet its primary endpoint of overall survival (OS) at the final analysis. CONTACT-01 is a phase III clinical trial evaluating Cabometyx® (cabozantinib) in combination with atezolizumab (Tecentriq®) versus docetaxel in patients with unmutated metastatic non-small cell lung cancer (NSCLC) who experienced disease progression on or after treatment with an immune checkpoint inhibitor and platinum-containing chemotherapy. Howard Mayer, M.D., Executive Vice President, Head of Research and Development at Ipsen, said: “The results from the CONTACT-01 clinical trial have shown the challenge of treating NSCLC patients after prior lines of treatment have failed. While the findings of the study have not met the primary endpoint in this setting, we remain confident in the clinical efficacy of cabozantinib alone and in combination with another treatment in existing indications in difficult-to-treat tu
Verisign Reports Internet Has 349.9 Million Domain Name Registrations at the End of the Third Quarter of 20228.12.2022 21:57:00 CET | Press release
VeriSign, Inc. (NASDAQ: VRSN), a global provider of domain name registry services and internet infrastructure, today announced that the third quarter of 2022 closed with 349.9 million domain name registrations across all top-level domains, a decrease of 1.6 million domain name registrations, or 0.4%, compared to the second quarter of 2022.1,2 Domain name registrations have increased by 11.5 million, or 3.4%, year over year.1,2 The .com and .net TLDs had a combined total of 174.2 million domain name registrations in the domain name base3 at the end of the third quarter of 2022, a decrease of 0.2 million domain name registrations, or 0.1%, compared to the second quarter of 2022. The .com and .net TLDs had a combined increase of 2.1 million domain name registrations, or 1.2%, year over year. As of Sept. 30, 2022, the .com domain name base totaled 160.9 million domain name registrations, and the .net domain name base totaled 13.2 million domain name registrations. New .com and .net domain